コンテンツへスキップ
Merck

[The course and treatment of epilepsy in children with tuberose sclerosis].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2012-09-18)
M Iu Dorofeeva, E D Belousova
要旨

Tuberous sclerosis complex is a multisystem genetic disorder. Epilepsy is very common in tuberous sclerosis and occurs in 75-92% of affected individuals during their life-time. Onset usually occurs during childhood and up to one third of children with tuberous sclerosis will develop infantile spasms. Of all the possible manifestations of this complex disorder the resistant epilepsy, the cognitive and behavioral problems represent the area of greatest concern to parents, caregivers and physicians. Treatment of epilepsy in tuberous sclerosis is similar to epilepsy resulting from other cases and includes anticonvulsant medications, the epilepsy surgery, the vagus nerve stimulation and the ketogenic diet. Vigabatrin has been shown to be particularly effective in treating infantile spasms in the setting of tuberous sclerosis.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
(±)-ビガバトリン
Supelco
Vigabatrin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®